Indivior PLC $INDV Shares Acquired by Divisadero Street Capital Management LP

Divisadero Street Capital Management LP lifted its holdings in Indivior PLC (NASDAQ:INDV) by 2,372.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,362,605 shares of the company’s stock after buying an additional 3,226,605 shares during the period. Indivior makes up 3.5% of Divisadero Street Capital Management LP’s holdings, making the stock its 6th biggest position. Divisadero Street Capital Management LP owned 2.44% of Indivior worth $81,072,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of INDV. Goldman Sachs Group Inc. raised its holdings in Indivior by 18.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,368,996 shares of the company’s stock valued at $79,757,000 after acquiring an additional 1,299,425 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Indivior by 2,597.9% during the 1st quarter. Jane Street Group LLC now owns 995,013 shares of the company’s stock worth $9,327,000 after purchasing an additional 958,132 shares during the last quarter. ProShare Advisors LLC purchased a new stake in shares of Indivior in the second quarter valued at approximately $435,000. Geode Capital Management LLC grew its position in shares of Indivior by 1,122.6% in the second quarter. Geode Capital Management LLC now owns 1,576,915 shares of the company’s stock valued at $23,244,000 after purchasing an additional 1,447,939 shares in the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Indivior in the second quarter valued at approximately $855,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Indivior news, Director Mark Stejbach acquired 775 shares of the business’s stock in a transaction that occurred on Monday, January 5th. The stock was purchased at an average cost of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Keith Humphreys bought 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the transaction, the director directly owned 5,802 shares of the company’s stock, valued at $205,332.78. The trade was a 15.42% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 5,842 shares of company stock worth $203,342.

Indivior Stock Performance

Shares of Indivior stock opened at $31.11 on Monday. The firm has a market capitalization of $3.89 billion, a price-to-earnings ratio of 18.97 and a beta of 0.83. Indivior PLC has a fifty-two week low of $8.64 and a fifty-two week high of $38.00. The stock has a 50 day moving average of $33.73 and a 200 day moving average of $30.66.

Indivior (NASDAQ:INDV) last posted its earnings results on Thursday, February 26th. The company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The company had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Analysts forecast that Indivior PLC will post 1.22 EPS for the current year.

Wall Street Analyst Weigh In

INDV has been the topic of a number of analyst reports. Morgan Stanley reiterated an “overweight” rating and set a $36.00 price objective on shares of Indivior in a research report on Wednesday, December 3rd. HC Wainwright raised their target price on Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Weiss Ratings upgraded Indivior from a “hold (c)” rating to a “buy (b-)” rating in a report on Monday, March 2nd. Zacks Research cut shares of Indivior from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 13th. Finally, Northland Securities set a $50.00 price objective on shares of Indivior in a report on Tuesday, January 20th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $39.33.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.